ヨーロッパの臨床試験市場2022-2030:研究デザイン別(介入、観察、アクセス拡張)、相別(第I相、第II相、第II相、第IV相)、地域別

■ 英語タイトル:Europe Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, And Segment Forecasts, 2022 - 2030

調査会社Grand View Research社が発行したリサーチレポート(データ管理コード:GV22AP082)■ 発行会社/調査会社:Grand View Research
■ 商品コード:GV22AP082
■ 発行日:2022年3月23日
■ 調査対象地域:ヨーロッパ
■ 産業分野:医療
■ ページ数:114
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後3営業日)
■ 販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ヨーロッパの臨床試験市場2022-2030:研究デザイン別(介入、観察、アクセス拡張)、相別(第I相、第II相、第II相、第IV相)、地域別]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

グランドビューリサーチ社は、ヨーロッパの臨床試験市場規模が2022年から2030年の間に年平均5.7%成長し、2030年までに202億ドルに達すると予測しています。本調査レポートでは、臨床試験のヨーロッパ市場を広く調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、研究デザイン別分析、相別分析、国別分析、企業情報などの項目を掲載しています。

Europe Clinical Trials Market Growth & Trends
The Europe clinical trials market size is expected to reach USD 20.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2022 to 2030. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed to the market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely to promote the growth of the market.

The demand for personalized medicines has significantly improved in the region owing to significant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely to promote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.

For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 – 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.

Europe was one the worst affected region by the COVID-19 pandemic, owing to which public organizations in the region made significant funding in research to boost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged to invest USD 679 million to support the development of COVID-19 vaccines. Owing to the pandemic several research centers were shut down due to the national lockdown implemented by the government authorities, owing to which several clinical trial organizations opted for in silico trials and virtual clinical trials to speed up the research process. Such actions had profited the growth of the market.

Europe Clinical Trials Market Report Highlights

• The phase I trial segment is projected to witness a remarkable growth rate of 6.1% over the forecast period. This can be attributed to the significant R&D spending by public and private organizations to support new researches

• The interventional study design segment held the largest market share of 78.6% in 2021 owing to the greater accuracy offered by these studies, as compared to other clinical study designs

• European countries such as Germany and the U.K. are spearheading the revenue share, as these have a large patient pool and the presence of advanced medical infrastructure

*** レポート目次(コンテンツ)***

Table of Content

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Study Design
1.1.2 Phase
1.1.3 Country Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective – 1: Understanding the market dynamics
1.10.2 Objective – 2: Understanding the market estimates and forecasts
1.10.3 Objective – 3: Understanding the attributes such as strategy framework
1.10.4 Objective – 4: Understanding the key service and application scopes to conclude on the market size
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
Chapter 3 Europe Clinical Trials Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 PARENT Market OUTLOOK
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing Adoption Of New Technology In Clinical Research
3.3.1.2 Shift Toward Personalized Medicine
3.3.1.3 Growing Disease Variation And Prevalence
3.3.1.4 Growth In Cro Market
3.3.2 Market Restraint Analysis
3.3.2.1 Regulations In New Drug Development
3.3.2.2 Regulations In New Drug Development
3.3.2.3 Pricing Pressure
3.4. Clinical Category Drivers & Restraints
3.5 Europe clinical trials Market: Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 Pestel Analysis
3.5.3 Major Deals & Strategic Alliances Analysis
3.6 Analysis of Total Number of Clinical Trial Studies Conducted, by Countries
3.6.1 Analysis of Total Number of Clinical Trial Studies Conducted, by Countries
3.7 Cost Breakdown analysis for CRO’s
3.7.1 Percent Of Outsourced Vs In-House Clinical Trial Categories
3.7.2 Cost Breakdown Analysis For Cro’s By Phase I, II, & III
3.7.3 Cost Breakdown Analysis For Cro’s By Phase I, II, & III FOR Germany
3.8 Covid-19 Impact Analysis
Chapter 4 Europe clinical trials Market: Study Design Segment Analysis
4.1 Europe Clinical Trials Market: Definition & Scope
4.2 Europe Clinical Trials Market: Market Share Analysis, 2021 & 2030
4.3 Interventional Trials
4.3.1 Interventional trials studies market, 2018 – 2030 (USD Million)
4.4 Observational Trials
4.4.1 Observational trials studies market, 2018 – 2030 (USD Million)
4.5 Expanded access Trials
4.5.1 Expanded access studies market, 2018 – 2030 (USD Million)
Chapter 5 Europe clinical trials Market: Phase Segment Analysis
5.1 Europe clinical trials Market: Definition & Scope
5.2 Europe clinical trials Market: Market Share Analysis, 2021 & 2030
5.3 Phase I
5.3.1 Phase I market, 2018 – 2030 (USD Million)
5.4 Phase II
5.4.1 Phase II market, 2018 – 2030 (USD Million)
5.5 Phase III
5.5.1 Phase III market, 2018 – 2030 (USD Million)
5.6 Phase IV
5.6.1 Phase IV market, 2018 – 2030 (USD Million)
Chapter 6 Europe Clinical Trials Market: Country Analysis
6.1 Europe clinical trials Market: Definition & Scope
6.2 Country Market Snapshot
6.3 Country Market Share and Leading Players, 2020
6.3.1 U.K.
6.3.2 Germany
6.3.3 France
6.3.4 Italy
6.3.5 Spain
6.4 Europe clinical trials Market: Market Share Analysis, 2021 & 2030
6.5 Europe
6.5.1 Europe Europe clinical trials market, 2018 – 2030 (USD Million)
6.5.2 U.K.
6.5.2.1 U.K. Europe clinical trials market, 2018 – 2030 (USD Million)
6.5.3 Germany
6.5.3.1 Germany Europe clinical trials market, 2018 – 2030 (USD Million)
6.5.4 France
6.5.4.1 France Europe clinical trials market, 2018 – 2030 (USD Million)
6.5.5 Italy
6.5.5.1 Italy Europe clinical trials market, 2018 – 2030 (USD Million)
6.5.6 Spain
6.5.6.1 Spain Europe clinical trials market, 2018 – 2030 (USD Million)
Chapter 7 Company Profiles
7.1 IQVIA Holdings, Inc.,
7.1.1Company Overview
7.1.2 Financial Performance
7.1.3 Service Benchmarking
7.1.4 Strategic Initiatives
7.2 Parexel International Corporation
7.2.1 Company Overview
7.2.2 Service Benchmarking
7.2.3 Strategic Initiatives
7.3 PPD, Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Service Benchmarking
7.3.4 Strategic Initiatives
7.4 Syneos Health
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Service Benchmarking
7.4.4 Strategic Initiatives
7.5 Eli Lilly and Company
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Service Benchmarking
7.5.4 Strategic Initiatives
7.6 Novo Nordisk A/S
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Service Benchmarking
7.6.4 Strategic Initiatives
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Service Benchmarking
7.7.4 Strategic Initiatives
7.8 Dr. Notghi Contract Research GmbH
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Service Benchmarking
7.9 Charite Research Organisation GmbH
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Service Benchmarking
7.9.4 Strategic Initiatives
7.10 Janssen Global Services, LLC
7.10.1 Company Overview
7.10.2 Service Benchmarking
7.10.3 Strategic Initiatives
7.11 Janssen Global Services, LLC
7.11.1 Company Overview
7.11.2 Financial Performance
7.11.3 Service Benchmarking
7.11.4 Strategic Initiatives
7.12 KFGN
7.12.1 Company Overview
7.12.2 Financial Performance
7.12.3 Service Benchmarking
7.13 Clariness
7.13.1 Company Overview
7.13.2 Service Benchmarking
7.14 Invisio Clinical Studies Consulting GmbH
7.14.1 Company Overview
7.14.2 Financial Performance
7.14.3 Service Benchmarking
Chapter 8 KOL Commentary
Chapter 9 Recommendations

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 List of Major Deals
Table 4 Average cost of clinical trials in major European countries
Table 5 Europe Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 6 Europe Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 7 U.K. Clinical trials Market, by Country, 2018 - 2030 (USD Million)
Table 8 U.K. Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 9 U.K. Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 10 Germany Clinical trials Market, by Country, 2018 - 2030 (USD Million)
Table 11 Germany Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 12 Germany Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 13 France Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 14 France Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 15 France Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 16 Italy Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 17 Italy Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 18 Italy Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 19 Spain Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 20 Spain Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
Table 21 Spain Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information of Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Europe Clinical Trials Market snapshot (2021)
Fig. 10 Europe Clinical Trials Market segmentation
Fig. 11 Parent market outlook (2021)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Performance on precision medicine availability vs. Biomarker testing by country
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Clinical Category Drivers & Restraints
Fig. 17 Porter’s five forces analysis
Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 19 Germany Cost Per Indication (Million)
Fig. 20 U.K. Cost Per Indication (Million)
Fig. 21 France Cost Per Indication (Million)
Fig. 22 Italy Cost Per Indication (Million)
Fig. 23 Spain Cost Per Indication (Million)
Fig. 24 Total number of Clinical Trials By Country in 2021
Fig. 25 Europe (All Major Countries)
Fig. 26 Germany
Fig. 27 Europe (Average of all the major countries
Fig. 28 Percent of Outsourced vs In-house of Key Clinical Trial Categories (Trend across 2018-2020)
Fig. 29 Cost Breakdown by Phase I (Overall Europe)
Fig. 30 Cost Breakdown by Phase II (Overall Europe)
Fig. 31 Cost Breakdown by Phase III (Overall Europe)
Fig. 32 Cost Breakdown by Phase I (Germany)
Fig. 33 Cost Breakdown by Phase II (Germany)
Fig. 34 Cost Breakdown by Phase III (Germany)
Fig. 35 Europe Clinical Trials Market study design outlook: Segment dashboard
Fig. 36 Europe Clinical Trials Market: Study design movement analysis
Fig. 37 Interventional studies market, 2018 - 2030 (USD Million)
Fig. 38 Observational studies market, 2018 - 2030 (USD Million)
Fig. 39 Expanded access studies market, 2018 - 2030 (USD Million)
Fig. 40 Europe Clinical Trials Market phase outlook: Segment dashboard
Fig. 41 Europe Clinical Trials Market: Phase movement analysis
Fig. 42 Phase I market, 2018 - 2030 (USD Million)
Fig. 43 Phase II market, 2018 - 2030 (USD Million)
Fig. 44 Phase III market, 2018 - 2030 (USD Million)
Fig. 45 Phase IV market, 2018 - 2030 (USD Million)
Fig. 46 Country -wise market: Key takeaways
Fig. 47 Country outlook, 2021 & 2030
Fig. 48 Europe market, 2018 - 2030 (USD Million)
Fig. 49 U.K. market, 2018 - 2030 (USD Million)
Fig. 50 Germany market, 2018 - 2030 (USD Million)
Fig. 51 France market, 2018 - 2030 (USD Million)
Fig. 52 Italy market, 2018 - 2030 (USD Million)
Fig. 53 Spain market, 2018 - 2030 (USD Million)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GV22AP082 )"ヨーロッパの臨床試験市場2022-2030:研究デザイン別(介入、観察、アクセス拡張)、相別(第I相、第II相、第II相、第IV相)、地域別" (英文:Europe Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, And Segment Forecasts, 2022 - 2030)はGrand View Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。